A new blood test holds out the possibility of predicting the development of Alzheimer's Disease years before a clinical diagnosis can be made. Three new studies support the effectiveness of AlzoSure Predict in identifying individuals with high risk of Alzheimer disease up to 6 years prior to symptom onset. The test is able to differentiate between subjective memory concerns, mild cognitive impairment and Alzheimer's with 95% accuracy.
"The simplicity and affordability of our blood-based biomarker test means that it will be available to individuals in primary care settings, which will make widespread screening feasible. This in turn will help spur the development of new drugs for Alzheimer's Disease, which can then be widely administered early in the disease process, when the chances for slowing and stopping the cognitive ravages of Alzheimer's are the greatest,” said Paul Kinnon, chief executive officer, Diadem Biotheraputics, developer of the test.
While this is an early warning tool and not a cure or a treatment, it will allow Alzheimer's patients to begin treatment years before any clinical symptoms can be observed. This should greatly improve the chances of slowing the progression of the disease.
No comments:
Post a Comment